Diapositive 1

Hypofx RT or SBRT 48%

Surgery and RT 24%

Chemo-beam 8%

Hypofx RT and chemo-beam 12%

Surgery 4%

Pemetrexed 67%

Erlotinib 8%

Afatinib 4%

Bevacizumab 4%

Observation 17%



Phase II

randomized trial

, 49 patients enrolled



Stage IV NSCLC,

3 or fewer metastases



Primary Endpoint:

PFS



First line therapy with 4+ platinum based doublet or 3+ months of EGFR or ALK

inhibitors (if mutated)



Patients randomly assigned to:

A. Local therapy

B. Maintenance

Gomez DR. et al. Lancet Oncol 2016

20% received

Chemo-radiation